行情

FPRX

FPRX

Five Prime
NASDAQ

实时行情|Nasdaq Last Sale

3.230
+0.030
+0.94%
已收盘, 16:00 11/19 EST
开盘
3.200
昨收
3.200
最高
3.370
最低
3.180
成交量
33.43万
成交额
--
52周最高
13.97
52周最低
3.180
市值
1.18亿
市盈率(TTM)
-0.7783
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FPRX 新闻

  • The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
  • Benzinga.21小时前
  • Our Take On Five Prime Therapeutics
  • Seeking Alpha - Article.1天前
  • Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.11/12 14:22
  • Daily Insider Ratings Round Up 11/7/19
  • Seeking Alpha - Article.11/11 19:28

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

FPRX 简况

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
展开

Webull提供Five Prime Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。